PRX-08066 is primarily investigated for its potential therapeutic applications in treating pulmonary arterial hypertension (PAH). It functions as a selective serotonin receptor antagonist, targeting the 5-HT2B receptor, which plays a role in the proliferation of pulmonary artery smooth muscle cells. By inhibiting this receptor, PRX-08066 aims to reduce vascular remodeling and lower pulmonary artery pressure, thereby improving symptoms and progression of PAH. Its development highlights its potential as a targeted treatment option for patients suffering from this chronic and debilitating condition.